Vinnikov et al., 2022 - Google Patents
Clinical applications of biological dosimetry in patients exposed to low dose radiation due to radiological, imaging or nuclear medicine proceduresVinnikov et al., 2022
- Document ID
- 1260361209233492822
- Author
- Vinnikov V
- Belyakov O
- Publication year
- Publication venue
- Seminars in Nuclear Medicine
External Links
Snippet
Radiation dosimetric biomarkers have found applications beyond radiation protection area and now are actively introduced into clinical practice. Cytogenetic assays appeared to be a valuable tool for individualized quantifying radiation effects in patients, with high capability …
- 238000000034 method 0 title abstract description 76
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hänscheid et al. | Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days | |
May et al. | Induction and repair of DNA double-strand breaks in blood lymphocytes of patients undergoing 18 F-FDG PET/CT examinations | |
Niemeijer et al. | Study of 89Zr-pembrolizumab PET/CT in patients with advanced-stage non–small cell lung cancer | |
Chen et al. | 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy | |
Lassmann et al. | In vivo formation of γ-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer | |
Dehdashti et al. | Assessment of cellular proliferation in tumors by PET using 18F-ISO-1 | |
Challapalli et al. | 18F-ICMT-11, a caspase-3–specific PET tracer for apoptosis: biodistribution and radiation dosimetry | |
Liu et al. | PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor–selective tracer 11C-PD153035 in humans | |
Eberlein et al. | DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy | |
Eberlein et al. | DNA damage in blood lymphocytes in patients after 177 Lu peptide receptor radionuclide therapy | |
Verburg et al. | Dosimetry-guided high-activity 131 I therapy in patients with advanced differentiated thyroid carcinoma: initial experience | |
Geisel et al. | DNA double-strand breaks as potential indicators for the biological effects of ionising radiation exposure from cardiac CT and conventional coronary angiography: a randomised, controlled study | |
Pathmanandavel et al. | Evaluation of 177Lu-PSMA-617 SPECT/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN) | |
John et al. | 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy | |
Tolvanen et al. | Safety, biodistribution, and radiation dosimetry of 18F-rhPSMA-7.3 in healthy adult volunteers | |
Torizuka et al. | Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET | |
Liu et al. | Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer | |
Livingston et al. | Cytogenetic effects of radioiodine therapy: a 20-year follow-up study | |
Bozkurt et al. | Sister chromatid exchanges in lymphocytes of nuclear medicine physicians | |
Grawé et al. | Evaluation of the reticulocyte micronucleus assay in patients treated with radioiodine for thyroid cancer | |
Vinnikov et al. | Clinical applications of biological dosimetry in patients exposed to low dose radiation due to radiological, imaging or nuclear medicine procedures | |
Taylor et al. | Radiation-induced DNA damage and the relative biological effectiveness of 18F-FDG in wild-type mice | |
Erselcan et al. | Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship | |
Sciuto et al. | The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223 Ra: first in human study | |
Manning et al. | Quantifying murine bone marrow and blood radiation dose response following 18F-FDG PET with DNA damage biomarkers |